These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35934210)

  • 1. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.
    Kozera E; Flora A; Frew JW
    J Am Acad Dermatol; 2022 Dec; 87(6):1440-1442. PubMed ID: 35934210
    [No Abstract]   [Full Text] [Related]  

  • 2. Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature.
    Martora F; Scalvenzi M; Ruggiero A; Potestio L; Battista T; Megna M
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109759
    [No Abstract]   [Full Text] [Related]  

  • 3. Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.
    Med Lett Drugs Ther; 2019 Nov; 61(1585):183-185. PubMed ID: 31770358
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of upadacitinib in rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa.
    Ring HC; Thomsen SF
    Br J Dermatol; 2022 Aug; 187(2):274. PubMed ID: 35122235
    [No Abstract]   [Full Text] [Related]  

  • 7. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
    Alavi A; Hamzavi I; Brown K; Santos LL; Zhu Z; Liu H; Howell MD; Kirby JS
    Br J Dermatol; 2022 May; 186(5):803-813. PubMed ID: 34978076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox.
    Sibbald C; Alhusayen R
    Br J Dermatol; 2022 May; 186(5):768-769. PubMed ID: 35415896
    [No Abstract]   [Full Text] [Related]  

  • 9. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy for Hidradenitis Suppurativa/acne inversa: Case report.
    Zhang Y; Yang Y; Zou X
    Photodiagnosis Photodyn Ther; 2018 Jun; 22():251-252. PubMed ID: 29709603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.
    Świerczewska Z; Lewandowski M; Surowiecka A; Barańska-Rybak W
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
    Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
    Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
    Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
    Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
    N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication.
    Mohamed MF; Klünder B; Othman AA
    Clin Pharmacokinet; 2020 May; 59(5):531-544. PubMed ID: 31867699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
    Guttman-Yassky E; Thyssen JP; Silverberg JI; Papp KA; Paller AS; Weidinger S; Chih-Ho Hong H; Hendrickson B; Dilley D; Tenorio AR; Ladizinski B; Chu AD; Liu J; Irvine AD
    J Allergy Clin Immunol; 2023 Jan; 151(1):172-181. PubMed ID: 36195170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
    Guttman-Yassky E; Thaçi D; Pangan AL; Hong HC; Papp KA; Reich K; Beck LA; Mohamed MF; Othman AA; Anderson JK; Gu Y; Teixeira HD; Silverberg JI
    J Allergy Clin Immunol; 2020 Mar; 145(3):877-884. PubMed ID: 31786154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.